tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-19-23tumors-336Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSОпыт применения комбинации ELF в индукционной химиотерапии первой линии метастатического рака желудкаExperience of the use of combination of ELF in the induction first-line chemotherapy for metastatic gastric cancerНаримановМ. Н.NarimanovM. N.

д.м.н., с.н.с., отделение клинической фармакологии и химиотерапии

MD, PhD, DSc, Department of Clinical Pharmacology and Chemotherapy

mehtin@mail.ruТюляндинС. А.TjulandinS. A.

д.м.н., профессор, заведующий отделением клинической фармакологии и химиотерапии

MD, PhD, DSc, Professor, Department of Clinical Pharmacology and Chemotherapy

ФГБУ «РОНЦ им. Н. Н. Блохина», МоскваРоссияN. N. Blokhin Russian Cancer Research Center, MoscowRussian Federation201720072017021923Copyright © Нариманов М.Н., Тюляндин С.А., 20172017Нариманов М.Н., Тюляндин С.А.Narimanov M.N., Tjulandin S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/336

Комбинация ELF (этопозид, 5-фторурацил, лейковорин) при метастатическом раке желудка используется с 1980-х годов, но до последнего времени часто применяется в современной химиотерапии диссеминированного рака желудка. В настоящем исследовании проанализировано 60 историй болезни пациентов отделений клинической фармакологии и химиотерапии. В нашей работе мы решили изучить непосредственные и отдаленные результаты лечения комбинацией ELF на собственной группе больных. В настоящее время в арсенале противоопухолевых комбинаций для лечения диссеминированного рака желудка имеется ряд новых режимов с включением доцетаксела, иринотекана, оксалиплатина, и место комбинации ELF неясно в противоопухолевой химиотерапии рака желудка.

The combination of ELF (etoposide, 5-fluorouracil, leucovorin) for metastatic gastric cancer is used since 1980-ies, but until recently, is also often used in modern chemotherapy of metastatic gastric cancer. In the modern arsenal of anticancer combinations for the treatment of metastatic gastric cancer there is a number of new modes with the incorporation of docetaxel, irinotecan, oxaliplatin and place of the combination of ELF in anticancer chemotherapy of gastric cancer is unclear. In our study, we analyzed 60 histories of patients of the departments of clinical pharmacology and chemotherapy. We studied immediate and long-term results of treatment with a combination of ELF for their own group of patients. All patients were treated 344 therapeutic cycles of chemotherapy, median courses was 6 (1–6). Treatment failed to gain control over the symptoms of the disease failed in 23 (38,3%) patients. As a result of chemotherapy, 8 patients (13.3%) showed partial tumor response. 40 patients noted stabilization of the process (66.6%). For immediate results – the median overall survival was 8.4 months. Given the low toxicity, a high percentage of the disease control and control of clinical symptoms of the disease treatment has every right to exist and use in clinical practice as an induction first-line chemotherapy of metastatic gastric cancer. 

рак желудкахимиотерапиявепезид5-фторурациллейковоринgastric cancerchemotherapyvepeside5-fluorouracilleucovorinReferencesДавыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. // Вестник Российского онкологического научного центра имени Н.Н. Блохина РАМН. 2008. Т. 19. № 2. [Davydov M. I., Aksel E.M. Statistics of malignant neoplasms in Russia and CIS countries in 2006, Bulletin of the Russian oncological scientific center named after N.N. Blokhin of the RAMS, 2008, Vol. 18, No. 2. (In Russ.)].Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. // Вестник Российского онкологического научного центра имени Н.Н. Блохина РАМН. 2008. Т. 19. № 2. [Davydov M. I., Aksel E.M. Statistics of malignant neoplasms in Russia and CIS countries in 2006, Bulletin of the Russian oncological scientific center named after N.N. Blokhin of the RAMS, 2008, Vol. 18, No. 2. (In Russ.)].Ferlay J., Bray F., Pisani P. et al. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC cancerbase, Lyon: IARC Press, 2004, No. 5, Version 2.0.Ferlay J., Bray F., Pisani P. et al. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC cancerbase, Lyon: IARC Press, 2004, No. 5, Version 2.0.World Health Organization. The World Health Report 2003, Geneva: WHO, 2003.World Health Organization. The World Health Report 2003, Geneva: WHO, 2003.Correa P., Chen V.W. Gastric cancer, Cancer Surv., 1994, Vol. 19–20, pp. 55–76.Correa P., Chen V.W. Gastric cancer, Cancer Surv., 1994, Vol. 19–20, pp. 55–76.Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors, J. Clin. Epidemiol., 2003, Vol. 56, pp. 1–9.Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors, J. Clin. Epidemiol., 2003, Vol. 56, pp. 1–9.Powell J., McConkey C.C. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites, Br. J. Cancer, 1990, Vol. 62, pp. 440–3.Powell J., McConkey C.C. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites, Br. J. Cancer, 1990, Vol. 62, pp. 440–3.Verdecchia A., Corazziari I., Gatta G. et al. Explaining gastric cancer survival differences among European countries, Int. J. Cancer, 2004, Vol. 109, pp. 737–41.Verdecchia A., Corazziari I., Gatta G. et al. Explaining gastric cancer survival differences among European countries, Int. J. Cancer, 2004, Vol. 109, pp. 737–41.Fielding J.W. L, Powell J., Allum W.H. Cancer of the stomach, London: The Macmillan Press, 1989.Fielding J.W. L, Powell J., Allum W.H. Cancer of the stomach, London: The Macmillan Press, 1989.Hoichi Kato. Cancer Statistics in Japan, 2008.Hoichi Kato. Cancer Statistics in Japan, 2008.Гарин А.М., Базин И.С. Злокачественные опухоли пищеварительной системы. М.: Инфомедиа Паблишерз, 2003. [Garin A.M., Bazin I.S. Malignant tumors of the digestive system. Moscow: Infomedia Publishers, 2003, 264 p. (In Russ)].Гарин А.М., Базин И.С. Злокачественные опухоли пищеварительной системы. М.: Инфомедиа Паблишерз, 2003. [Garin A.M., Bazin I.S. Malignant tumors of the digestive system. Moscow: Infomedia Publishers, 2003, 264 p. (In Russ)].Berrino F., de Angelis R., Sant M. et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study, Lancet Oncol., 2007, Vol. 8, No. 9, pp. 773–783.Berrino F., de Angelis R., Sant M. et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study, Lancet Oncol., 2007, Vol. 8, No. 9, pp. 773–783.

The authors declare that there are no conflicts of interest present.